Head to Head Contrast: Whitehawk Therapeutics (NASDAQ:WHWK) vs. Biogen (NASDAQ:BIIB)

Whitehawk Therapeutics (NASDAQ:WHWK) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Whitehawk Therapeutics and Biogen”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14 million	28.11	-$20.60 million	($1.12)	-3.14
Biogen	$9.89 billion	3.37	$1.29 billion	$5.65	39.95

Biogen has higher revenue and earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Whitehawk Therapeutics and Biogen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-53.89%	-49.97%
Biogen	8.32%	11.18%	6.88%

Volatility and Risk

Whitehawk Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Whitehawk Therapeutics and Biogen, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1	0	7	0	2.75
Biogen	1	13	17	1	2.56

Whitehawk Therapeutics currently has a consensus price target of $8.33, suggesting a potential upside of 136.74%. Biogen has a consensus price target of $231.07, suggesting a potential upside of 2.38%. Given Whitehawk Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Whitehawk Therapeutics is more favorable than Biogen.

Summary

Biogen beats Whitehawk Therapeutics on 10 of the 15 factors compared between the two stocks.

About Whitehawk Therapeutics

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin’s lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin’s lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer’s disease and dementia, neuromuscular disorders, Parkinson’s disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.